1-(2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol | 477965-95-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1-(2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol
• 英文别名: 1-(2-aminopropyl)-8,9-dihydro-7H-pyrano[2,3-g]indazol-8-ol
• CAS: 477965-95-0
• 化学式: C₁₃H₁₇N₃O₂
• 分子量: 247.297
• InChiKey: CMXWVAVWKSWVHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  73.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Pyranoindazoles and their use for the treatment of glaucoma
  申请人：——

  公开号：US20030171418A1

  公开（公告）日：2003-09-11

  Pyranoindazoles are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of the present invention.

  吡啶并吡唑类化合物已被披露。还公开了降低和控制正常或升高眼内压力的方法，以及使用含有本发明化合物之一或多个的组合物治疗青光眼的方法。
• PROCESS FOR PREPARING PYRANOINDAZOLE SEROTONERGIC RECEPTOR AGONISTS
  申请人：CONROW Raymond E.

  公开号：US20080033183A1

  公开（公告）日：2008-02-07

  Described are methods of making pyranoindazoles comprising reacting with a reducing agent a protected halohydrin comprising a secondary carbamate to form a pyranoindazole. In preferred embodiments the secondary carbamate is a benzyl carbamate. Also preferred are embodiments wherein the reacting is preceded by reacting a protected halohydrin with a first organometallic compound. The pyranoindazoles thus formed by the described methods are preferably pharmaceutically active products.

  描述了制备吡喃吲唑的方法，包括将含有次级碳酸酯的保护卤代醇与还原剂反应以形成吡喃吲唑。在优选实施例中，次级碳酸酯是苄基碳酸酯。还优选了通过将保护卤代醇与第一有机金属化合物反应来预先进行反应的实施例。因此，通过所述方法形成的吡喃吲唑通常是具有药用活性的产品。
• Novel fused indazoles and indoles and their use for the treatment of glaucoma
  申请人：——

  公开号：US20040106597A1

  公开（公告）日：2004-06-03

  Novel fused indazoles and indoles are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of the present invention.

  本发明揭示了融合吲唑和吲哚的新型化合物。同时，本发明还揭示了使用含有本发明化合物中的一种或多种化合物的组合物进行降低和控制正常或升高的眼内压的方法，以及治疗青光眼的方法。
• PYRANOINDAZOLE CYCLIC CARBONATES AND METHODS OF USE
  申请人：DELGADO Pete

  公开号：US20080058533A1

  公开（公告）日：2008-03-06

  Described are methods of making pyranoindazole compounds comprising converting a pyranoindazole diol mixture to form a diastereomeric mixture of cyclic pyranoindazole carbonates, separating the mixture of cyclic pyranoindazole carbonates, and converting at least one of the separated diastereoisomeric cyclic pyranoindazole carbonates by hydrogenolysis. Also disclosed are intermediates useful for such and additional methods.

  本文描述了制备吡喃吲唑化合物的方法，包括将吡喃吲唑二醇混合物转化为环状吡喃吲唑碳酸酯的对映体混合物，分离环状吡喃吲唑碳酸酯混合物，并通过氢解反应转化至少一种分离的对映体环状吡喃吲唑碳酸酯。此外还公开了用于这种和其他方法的中间体。
• Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
  申请人：Schneider Wayne L.

  公开号：US20060073172A1

  公开（公告）日：2006-04-06

  The present invention provides stable ophthalmic solutions comprising a compound with serotonergic 5-HT 2 receptor activity and at least one stabilizer, together with methods of using such solutions to treat glaucoma and to lower intraocular pressure.

  本发明提供了稳定的眼科溶液，其中包含一种具有血清素能 5-HT 2 受体活性的化合物和至少一种稳定剂，以及使用这种溶液治疗青光眼和降低眼压的方法。